TransBioLine submits its 1st Qualification Plan to the FDA
The TransBioLine consortium has been working for the past five years on discovery, validation and regulatory qualification of a variety of safety biomarkers for drug-induced organ injury. On Friday, February 9, 2024, the first Biomarker [...]